CLINICAL CASE 01
When Standard Labs Miss Disease
A fit, symptom-free 46-year-old man wanted to optimize his health. His routine labs looked reassuring. But the epigenetic biomarkers in his TruAge and TruHealth results revealed a hidden atherogenic pattern.
Follow-up testing that he'd never have done otherwise confirmed dyslipidemia, and a CT angiogram showed coronary plaque.
Standard screening missed these subtle shifts in the patient’s biology. Epigenetics detected cardiovascular disease years before symptoms would have been felt.
Follow-up testing that he'd never have done otherwise confirmed dyslipidemia, and a CT angiogram showed coronary plaque.
Standard screening missed these subtle shifts in the patient’s biology. Epigenetics detected cardiovascular disease years before symptoms would have been felt.
TRUAGE™ CLOCKS
Even his biological age agreed: he was aging slower than his peers.
Biological ages suggest he's doing most things right — but maybe not everything. Some risk may not be fully within his control.
OMICmAge™ / Biological Age
-4.5
Younger
SYMPHONYAge™ / Systems-level Age
-1.5
Younger
DunedinPACE™ / Pace of Aging
0.83
Aging Slowly
BIOMARKERS
But the epigenetics told a different story.
When we look at the combination of low PON1 and ApoA1 levels, alongside high ApoB and the presence of small dense LDL, it paints a concerning picture of cardiovascular risk, even for someone who is otherwise fit. These various indicators come together to highlight potential issues in the lipid and cardiovascular pathways.
CLINICAL ACTION
The signals sent him for a closer look he’d never have been referred for.
Based on the epigenetic biomarker results, his clinician sent him for further testing.